Hospital Pharmaceutical Drugs Market by Indications (Coronary Heart Diseases, Heart Failure, High Blood Pressure, Stroke, Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Acute Kidney Failure, Chronic Kidney Diseases, Diabetes, Glomerular Diseases, Alzheimer’s Disease, Epilepsy, Multiple Sclerosis, Parkinson’s Disease, Cancer Pain, Fibromyalgia, Neuropathic Pain, Osteoarthritis, Rheumatoid Arthritis, Amoebiasis, Candida Infection, Tuberculosis, Fungal Meningitis, Hepatitis A, Hepatitis B, Pneumonia, Shigellosis), Therapeutics (Anti-Adrenergic Drugs, Anti-Arrhythmic Drugs, Calcium Channel Blockers, Diuretic Drugs, 5-Alpha Reductase Inhibitors, Alkylating Agents, Anticholinergic Drugs, Anti-Hypertensive Agents, Anti-Metabolites, Diuretic Agents, Hormonal Agents, Immunomodulation Agents, Miscellaneous Drugs, Phosphate Binders, Neurology, Anti-Anxiety Agents, Antidepressant Drugs, Anti-Migraine Drugs, Anti-Psychotic Drugs, Anesthetic Drugs, Anticonvulsant Drugs, Non-Narcotics Analgesic Drugs, Non-Steroidal Anti-Inflammatory Drugs, Opioids, Antibacterial Drugs, Antifungal Drugs, Antiparasite Drugs, and Antiviral Drugs) and Applications (Cardiology, Oncology, Nephrology and Urology, Pain and Infection Categories) and Forecast 2017-2021

Hospital Pharmaceutical Drugs Market by Indications (Coronary Heart Diseases, Heart Failure, High Blood Pressure, Stroke, Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Acute Kidney Failure, Chronic Kidney Diseases, Diabetes, Glomerular Diseases, Alzheimer’s Disease, Epilepsy, Multiple Sclerosis, Parkinson’s Disease, Cancer Pain, Fibromyalgia, Neuropathic Pain, Osteoarthritis, Rheumatoid Arthritis, Amoebiasis, Candida Infection, Tuberculosis, Fungal Meningitis, Hepatitis A, Hepatitis B, Pneumonia, Shigellosis), Therapeutics (Anti-Adrenergic Drugs, Anti-Arrhythmic Drugs, Calcium Channel Blockers, Diuretic Drugs, 5-Alpha Reductase Inhibitors, Alkylating Agents, Anticholinergic Drugs, Anti-Hypertensive Agents, Anti-Metabolites, Diuretic Agents, Hormonal Agents, Immunomodulation Agents, Miscellaneous Drugs, Phosphate Binders, Neurology, Anti-Anxiety Agents, Antidepressant Drugs, Anti-Migraine Drugs, Anti-Psychotic Drugs, Anesthetic Drugs, Anticonvulsant Drugs, Non-Narcotics Analgesic Drugs, Non-Steroidal Anti-Inflammatory Drugs, Opioids, Antibacterial Drugs, Antifungal Drugs, Antiparasite Drugs, and Antiviral Drugs) and Applications (Cardiology, Oncology, Nephrology and Urology, Pain and Infection Categories) and Forecast 2017-2021

Hospital pharmaceuticals are medications and drugs administered to patients in hospital settings that include both in-patient and out-patient treatment. Increasing prevalence of diseases, affordability, rising awareness, and healthcare spending are some of the factors driving the hospital pharmaceuticals market growth in emerging economies of Asia Pacific and Rest of the World.

The global hospital pharmaceutical drugs market report estimates the market size (Revenue USD million – 2014 to 2021) for key market segments based on the indications (coronary heart diseases, heart failure, high blood pressure, stroke, breast cancer, colorectal cancer, lung cancer, prostate cancer, acute kidney failure, chronic kidney diseases, diabetes, glomerular diseases, Alzheimer’s disease, epilepsy, multiple sclerosis, Parkinson’s disease, cancer pain, fibromyalgia, neuropathic pain, osteoarthritis, rheumatoid arthritis, amoebiasis, candida infection, tuberculosis, fungal meningitis, hepatitis A, hepatitis B, pneumonia, shigellosis; while therapeutics include anti-adrenergic drugs, anti-arrhythmic drugs, calcium channel blockers, diuretic drugs, 5-alpha reductase inhibitors, alkylating agents, anticholinergic drugs, anti-hypertensive agents, anti-metabolites, diuretic agents, hormonal agents, immunomodulation agents, miscellaneous drugs, phosphate binders, neurology, anti-anxiety agents, antidepressant drugs, anti-migraine drugs, anti-psychotic drugs, anesthetic drugs, anticonvulsant drugs, non-narcotics analgesic drugs, non-steroidal anti-inflammatory drugs, opioids, antibacterial drugs, antifungal drugs, antiparasite drugs, and antiviral drugs) and therapeutic applications in cardiology, oncology, nephrology and urology, pain and infection categories, and forecasts growth trends (CAGR% – 2017 to 2021).

The global hospital pharmaceutical drugs market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global hospital pharmaceutical drugs market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.

Major players operating in the global hospital pharmaceutical drugs market and included in this report are AstraZeneca plc, Bayer AG, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Novartis, and Pfizer, Inc.

Category:
  1. Introduction
  2. Executive Summary
    • Market Size Estimation (Revenue USD Million, 2014-2021)
    • Forecast Estimation (Revenue USD Million and CAGR%, 2017-2021)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Drugs
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Drug Class or Drug (Brand) Type
    • Drug or Disorder Test
    • Indication Type
    • Drug Treatment
    • Mechanism of Action
    • Therapeutic Area or Nature of Application
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • IND, NDA filed, FDA, EMEA Approvals
  8. Pipeline Analysis(Phase 1, 2 and 3 Drugs)
    • Phase 3 Drugs Forecast Estimation (Approval to 2025)
    • Phase 1 and 2 Drugs – Qualitative Analysis
  9. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot (FY 2014-2016)
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  10. Recommendations
  11. References

Hospital Pharmaceutical Drugs Market

1. Indication Type
1.1. Cardiology
1.1.1. Coronary Heart Diseases
1.1.2. Heart Failure
1.1.3. High Blood Pressure
1.1.4. Stroke
1.1.5. Others
1.2. Oncology
1.2.1. Breast Cancer
1.2.2. Colorectal Cancer
1.2.3. Lung Cancer
1.2.4. Prostate Cancer
1.2.5. Others
1.3. Nephrology and Urology
1.3.1. Acute Kidney Failure
1.3.2. Chronic Kidney Diseases
1.3.3. Diabetes
1.3.4. Glomerular Diseases
1.3.5. Others
1.4. Neurology
1.4.1. Alzheimer’s Disease
1.4.2. Epilepsy
1.4.3. Multiple Sclerosis
1.4.4. Parkinson’s Disease
1.4.5. Others
1.5. Pain
1.5.1. Cancer Pain
1.5.2. Fibromyalgia
1.5.3. Neuropathic Pain
1.5.4. Osteoarthritis
1.5.5. Rheumatoid Arthritis
1.6. Infection
1.6.1. Amoebiasis
1.6.2. Candida Infection
1.6.3. Tuberculosis
1.6.4. Fungal Meningitis
1.6.5. Hepatitis A
1.6.6. Hepatitis B
1.6.7. Pneumonia
1.6.8. Shigellosis
1.6.9. Others

2. Therapeutic Application
2.1. Cardiology
2.1.1. Anti-Adrenergic Drugs
2.1.2. Anti-Arrhythmic Drugs
2.1.3. Calcium Channel Blockers
2.1.4. Diuretic Drugs
2.1.5. Others
2.2. Oncology
2.2.1. 5-Alpha Reductase Inhibitors
2.2.2. Alkylating Agents
2.2.3. Anticholinergic Drugs
2.2.4. Anti-Hypertensive Agents
2.2.5. Anti-Metabolites
2.2.6. Diuretic Agents
2.2.7. Hormonal Agents
2.2.8. Immunomodulation Agents
2.2.9. Miscellaneous Drugs
2.3. Nephrology and Urology
2.3.1. Phosphate Binders
2.3.2. Neurology
2.3.3. Anti-Anxiety Agents
2.3.4. Antidepressant Drugs
2.3.5. Anti-Migraine Drugs
2.3.6. Anti-Psychotic Drugs
2.4. Pain
2.4.1. Anesthetic Drugs
2.4.2. Anticonvulsant Drugs
2.4.3. Non-Narcotics Analgesic Drugs
2.4.4. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
2.4.5. Opioids
2.5. Infection
2.5.1. Antibacterial Drugs
2.5.2. Antifungal Drugs
2.5.3. Antiparasite Drugs
2.5.4. Antiviral Drugs

3. Company Profiles
3.1. AstraZeneca plc.
3.2. Bayer AG
3.3. Bristol-Myers Squibb Company
3.4. Eli Lilly and Company
3.5. GlaxoSmithKline plc
3.6. Johnson & Johnson
3.7. Merck & Co., Inc.
3.8. Novartis AG
3.9. Pfizer, Inc.
3.10. Sanofi-Aventis

Request market specific full ToC and sample pages for this report

Full Name*

Email*

Phone Number* [Please add country code]

Subject*

Message*